How is stem cell treatment for Degenerative Disc Disease done?
At Stem Cell Mexico, stem cell treatment for degenerative disc disease (DDD) is a structured, minimally invasive process centered on identifying the source of your pain and treating it precisely.

It begins with a review of your MRI and medical history, continues with a consultation with the doctor, a written plan and an in-person evaluation, and centers on an image-guided injection of allogeneic mesenchymal stem cells (MSCs) from Wharton's jelly of the umbilical cord. Depending on the findings, cells may be placed into the disc (intradiscal), the facet joints, the sacroiliac joints or surrounding tissues. The procedure is performed under local anesthesia, usually with light sedation if needed, followed by a short observation period, discharge with activity instructions and a rehabilitation plan. No autologous cells or other cell sources are used. Results vary between patients.
Why the process starts with finding the pain generator
Disc degeneration appears on the MRIs of many people who have no back pain, so an abnormal disc on imaging does not automatically explain your symptoms. Pain may come from the disc itself, the facet joints, the sacroiliac joints, muscles, ligaments or irritated nerves, and often from more than one source. Treating the wrong structure is one of the main reasons spine procedures fail. For this reason, the medical team combines imaging with your history and a physical examination to decide which structures, if any, should be treated.
A typical itinerary
- Day 1: pickup in the San Diego area, border crossing with a driver, laboratory tests and in-person consultation with the doctor, including a spine examination.
- Day 2: image-guided procedure, followed by observation and rest.
- Day 3: check-up with the doctor, activity instructions and return to San Diego.
Some patients complete the visit in a shorter time. The exact itinerary is confirmed in your written plan.
Step 1: Records review
You send:
- A recent lumbar or cervical MRI (no older than three months), with the images and the radiologist's report.
- X-rays, including flexion and extension views if available, to check for instability.
- Specialist notes from orthopedics, neurosurgery, pain medicine or physical medicine.
- Previous treatments: physical therapy, medications, injections or surgery, with dates and results.
- A complete medication list, especially blood thinners.
Step 2: Consultation with the doctor
A complimentary phone or video consultation allows the doctor to review your history, explain what regenerative treatment can and cannot do for DDD and discuss whether you may be a candidate. The doctor will explain what research shows: a 2026 meta-analysis of randomized trials suggests benefits in pain and function, while in the RESPINE trial patients improved in both the cell and placebo groups. Goals are made specific, for example sitting tolerance, walking distance, sleep or medication use, and baseline pain and disability scores are recorded.
Step 3: Written plan and preparation
If treatment is considered appropriate, you receive a written plan describing the cell dose, target structures, image guidance, itinerary, inclusions and costs. Typical preparation includes:
- Blood thinners are reviewed with the doctor and your prescribing physician; they are never stopped without medical guidance.
- Pausing anti-inflammatory painkillers, alcohol, tobacco and cannabis for about seven days before treatment, and supplements such as omega 3, turmeric and ginger for about five days before, as the doctor indicates.
- Avoiding corticosteroid injections in the area in the weeks before treatment, as the doctor indicates.
- Arriving fasting if sedation is planned.
- Arranging a companion for the day of the procedure.
Step 4: Arrival and evaluation
On arrival, you have blood tests, including a complete blood count, coagulation tests and other tests the doctor considers necessary, and an in-person examination. The doctor reviews your imaging, confirms the target structures and checks for any reason to postpone, such as fever, infection or uncontrolled blood pressure.
Step 5: The procedure
The cells
Allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. They are produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
How it is done
- You lie face down on a procedure table; light sedation may be offered for comfort.
- Vital signs are monitored throughout.
- The skin is cleaned with antiseptic and covered with sterile drapes; measures to reduce infection risk are followed as the doctor indicates.
- Local anesthetic numbs the skin and deeper tissues.
- Using fluoroscopy (X-ray guidance) or ultrasound, depending on the target, a thin needle is guided to the disc, facet joint, sacroiliac joint or soft tissue.
- For intradiscal treatment, needle position inside the disc is confirmed with imaging before the cells are injected slowly.
- The needle is removed and a small dressing is applied.
The procedure usually takes 30 to 60 minutes, depending on the number of levels and structures treated. Image guidance is essential in the spine: it helps place cells where they are intended and reduces the risk of injury to nerves and blood vessels.
The role of the route
A review in Frontiers in Immunology describes how the route of delivery determines where MSCs go and how long they remain. Local injection into the disc or joint places cells directly at the target, which is why it is the route studied in randomized trials of DDD.
Step 6: Observation
After the procedure, you rest in a recovery area for a period of observation. The team checks your vital signs, leg strength and sensation, and pain level. Most patients walk out of the clinic the same day. If sedation was used, you should not drive for the rest of the day, and a companion should stay with you that evening.
Step 7: Discharge and early recovery
Written instructions typically include:
- Temporary increase in back pain for several days is common, especially after intradiscal injection.
- Use ice and paracetamol (acetaminophen) as directed; avoid anti-inflammatory painkillers unless the doctor authorizes them.
- Relative rest for the first days, with short walks; avoid heavy lifting, bending and twisting for the period indicated.
- Avoid prolonged sitting and long drives when possible in the first days, or take frequent breaks.
- Seek care promptly for fever, increasing back pain over several days, new leg weakness or numbness, or problems with bladder or bowel control, which could indicate a complication such as disc infection.
No treatment is free of risk, and these instructions help detect problems early.
Step 8: Rehabilitation
After the initial recovery period, a progressive program is essential:
- Weeks 1 to 2: walking and gentle mobility.
- Weeks 2 to 6: guided core stabilization, flexibility and posture work with a physical therapist.
- Weeks 6 to 12 and beyond: progressive strengthening, conditioning and return to usual activities and sports.
The NICE guideline on low back pain (NG59) emphasizes exercise and staying active as the foundation of care, and cell therapy should support, not replace, this approach.
Step 9: Follow-up and measurement
- Follow-up calls at regular intervals.
- Repeat pain and disability scores (VAS and Oswestry Disability Index) at about 3, 6 and 12 months.
- Follow-up MRI only when your doctor considers it useful, since imaging changes do not always match symptoms.
- Coordination with your local physician and physical therapist.
Based on what patients tell us, many notice pain relief within days to weeks after a spinal application, although some discomfort in the treated area can last up to a month. Others improve more gradually over the following months, which is why our team stays in contact to follow your progress.
Traveling after a spine procedure
The return trip deserves planning. Sitting for long periods can aggravate pain in the first days. If you are flying home, consider an aisle seat so you can stand and walk periodically, and bring a small lumbar cushion. Use luggage with wheels and ask for help lifting bags into overhead bins. If you are driving, a companion who can share the driving is ideal.
Who may be a candidate
- Chronic low back or neck pain for at least six months that has not improved enough with structured conservative care.
- Imaging and examination consistent with disc-related or joint-related pain.
- No nerve compression requiring surgery, spinal instability, fracture, infection or tumor.
- No active infection and no cancer within the past five years.
- Commitment to rehabilitation.
Questions to ask during your evaluation
- Which structures will be treated, and why?
- What image guidance will be used?
- What should I expect in the first two weeks?
- What does my rehabilitation plan look like?
- How will results be measured?
Bottom line
Stem cell treatment for degenerative disc disease at Stem Cell Mexico follows a step-by-step process: records review, consultation, preparation, evaluation, an image-guided injection of Wharton's jelly MSCs into the structures identified as pain sources, observation, activity guidance, rehabilitation and follow-up with objective measures. Results vary between patients. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your back condition, goals and medical history.
References
- Rahyussalim et al. Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials. Asian Spine Journal, 2026 (opens in a new tab)
- RESPINE consortium. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Annals of the Rheumatic Diseases, 2024 (opens in a new tab)
- NICE guideline NG59: Low back pain and sciatica in over 16s, assessment and management (opens in a new tab)
- Caplan H, Olson SD, Cox CS Jr et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Frontiers in Immunology, 2019 (opens in a new tab)
